Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

IBD in 2016

Biologicals and biosimilars in IBD — the road to personalized treatment

Nature Reviews Gastroenterology & Hepatology volume 14, pages 74–76 (2017)Cite this article

Subjects

In 2016, personalized medicine for IBD has been evolving. Increasing comfort with biosimilar infliximab was achieved with 'real-life' data. Drugs with alternative modes of action confirmed substantial benefit, even in patients failing anti-TNF agents. Adipose-derived mesenchymal stem cells yielded a new treatment option for perianal fistulas.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ben-Horin, S. & Chowers, Y. Loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther. 33, 987–995 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Yarur, A. J. et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 65, 249–255 (2016).

    Article  CAS  PubMed  Google Scholar 

  3. Brandse, J. F. et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149, 350–355 (2015).

    Article  CAS  PubMed  Google Scholar 

  4. Gecse, K. B. et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J. Crohns Colitis 10, 133–140 (2016).

    Article  PubMed  Google Scholar 

  5. Ben-Horin, S. et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 65, 1132–1138 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Jørgensen, K. K. et al. Switching from originator infliximab to biosimilar CT-P13 compared to maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomised double-blind non-inferiority trial [abstract LB15]. UEG J. 4, 800–811 (2016).

    Google Scholar 

  7. Amiot, A. et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 14, 1593–1601 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 375, 1946–1960 (2016).

    Article  CAS  PubMed  Google Scholar 

  9. Wils, P. et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin. Gastroenterol. Hepatol. 14, 242–250 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Panés, J. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388, 1281–1290 (2016).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Medicine, Semmelweis University, Koranyi Sandor str. 2/a, Budapest, 1083, Hungary

    Krisztina B. Gecse & Péter L. Lakatos

Authors
  1. Krisztina B. Gecse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Péter L. Lakatos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Péter L. Lakatos.

Ethics declarations

Competing interests

K.B.G. has received consultancy fees from AbbVie, Amgen, Ferring, Hospira, MSD, Pfizer, Sandoz, Takeda and Tigenix. P.L.L. has received consultancy fees from AbbVie, Celgene, Celltrion, Ferring, Hospira, Mitsubichi Tanabe Pharma, MSD, Pfizer, Roche and Takeda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gecse, K., Lakatos, P. Biologicals and biosimilars in IBD — the road to personalized treatment. Nat Rev Gastroenterol Hepatol 14, 74–76 (2017). https://doi.org/10.1038/nrgastro.2016.206

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2016.206

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research